Breaking News

Trials & Filings in Brief: Jan. 7, 2014

By Gil Roth | January 7, 2014

Alitair, Celgene, Erytech, Galena, Neurocrine, Orexigen, Shield, TeaRx

Phase II
Erytech to begin pancreatic cancer study . . . read more

Galena enrolls first ovarian cancer patient . . . read more

Neurocrine Biosciences posts positive results in tardive dyskinesia . . . read more

TeaRx begins anticoagulant trial . . . read more

Phase III
Positive results for Shield's IDA treatment in IBD . . . read more

Approvals
Celgene's Abraxane approved in EU for pancreatic cancer . . . read more

Filings
Alitair gets orphan status for bronchiectasis treatment . . . read more

Orexigen gets Contrave PDUFA date . . . read more

blog comments powered by Disqus